Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant for children and adolescents with nocturnal enuresis
2025-521443-20-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nocturnal enuresis (NE) comparing Daridorexant with Placebo (2 arms). Primary endpoint: Change in wet nights per week. Planned start Mar 2026; status: authorised.
02
Drugs
daridorexant
03
Conditions
nocturnal enuresis (NE)
Beyond the preview
Go deeper on 2025-521443-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521443-20-00.